Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.